Cancer combination therapies by silencing of CTLA‐4, PD‐L1, and TIM3 in osteosarcoma

Abstract

Osteosarcoma (OS) is the most common orthopedic neoplasm, with a high metastasis rate and a dismal prognosis despite surgery and chemotherapy.Immunotherapies have offered cancer patients a ray of optimism, but their impact on OS has been disappointing. The objective of this study is to assess the effect of mono, dual, and triple combinations of CTLA-4, PD-L1, and TIM3 blockade on OS cell viability, apoptosis, and migration. The MG-63 and U-2 OS cell lines were transfected with mono, dual, and triple combinations of siRNAs specific for CTLA-4, PD-L1, and TIM3. After evaluation for transfection efficacy by qRT-PCR, MTT assay and flow cytometry were applied to assess cell viability and apoptosis rate in siRNA-transfected cells, respectively. Ultimately, the migration of transfected cells was measured by wound-healing assay. First, the qRT-PCR analysis revealed that in siRNA-transfected OS cells, CTLA-4, PD-L1, and TIM3 were downregulated. The MTT assay and flow cytometry results confirmed that silencing of these immune checkpoints in dual or triple combinations, but not in the single-agent blockade, significantly decreases cell viability and increases apoptosis, respectively. These effects were more significant when triple silencing was performed. Finally, the wound-healing assay revealed that dual and triple silencing of immune checkpoints significantly inhibits cell migration, with triple silencing exhibiting a greater effect. Our findings suggest that triple blockade of CTLA-4, PD-L1, and TIM3 is an effective strategy for inhibiting tumor cell progression and migration in OS, which

The role of TIM-3 in sepsis: a promising target for immunotherapy?

“…Accumulating evidence suggests that the interaction between TIM-3 and PD-1 synergistically suppresses T cell responses, promoting T cell exhaustion in sepsis ( 55 ). Furthermore, the co-expression of TIM-3 and CTLA-4 has been associated with suboptimal T cell function and worse clinical outcomes in sepsis patients ( 56 ). These interactions underscore the importance of comprehensive studies on multiple immune inhibitory pathways in sepsis, paving the way for novel combination immunotherapy strategies.…”

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

“…As well, experiments on solid tumor-bearing mice models demonstrated that triple knockdown of transcription factors involved in the expression of inhibitory receptors such as NR4A1, NR4A2, and NR4A3 enhance anti-tumor activity and survival of CAR T-cells ( 237 ). Likewise, the TGF-β signaling cascade induces suppression of T-cell expansion, effector function, and migration through upregulation of the inhibitory receptors PD-1 and T-cell immunoglobulin and mucin domain 3 (TIM-3) ( 238 ), which have been shown to implicate in various solid tumors development and progression ( 239 ). This has prompted researchers to engineer CAR T-cells to co-express a bispecific protein of anti-PD-1 fused with a TGF-β trap to concurrently hinder the PD-1/PD-L1 axis and the TGF-β signaling cascade ( 233 ).…”

Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment

“…The immune checkpoint ligand PD-L1 has been found to be overexpressed in a variety of solid tumors [ 199 ]. PD-L1 binds to its receptor PD-1, and blocking it has shown therapeutic potential in cancer therapy [ 200 ]. However, when PD-L1 blockade is combined with optimal dose IL-12 delivery, it induces a synergistic effect of enhancing anti-tumor immunity in cancer patients [ 201 ].…”